Investigators identified EP4 as a specific target for prostate cancer immunotherapy and demonstrated that YY001 inhibited the growth of prostate tumors by regulating the immune microenvironment and strongly synergized with anti-programmed cell death protein-1 antibodies.
[Clinical Cancer Research]
Sorry, but the selected Zotpress account can't be found.
